0 +

PGx CPT Codes

0 %

Payer Policies Tracked

0 x

Audit-Ready Reports

Synapse

PGx Revenue Defense Engine

SignalPGx attaches payer-ready CPT and ICD-10 coding, MolDX Z-code context, and medical-necessity documentation to every pharmacogenomic report before it is released, so the lab's billing team reviews and signs off on a defensible, audit-ready claim instead of reconstructing the coding and rationale after a denial.

Year

2026

Industry

PGx Reimbursement & Revenue Integrity

SERVICE USED

Evidence Interpretation, Report Automation

Challenge

PGx claims are routinely denied because CPT coding, ICD-10 medical necessity, and MolDX Z-code documentation are assembled by hand after the report already shipped.

(spx® — the problem)

Pharmacogenomic claims are routinely denied when CPT coding, ICD-10 medical-necessity, and MolDX Z-code documentation are assembled by hand after a report ships, leaving billing teams to reconstruct the justification for every appeal.

Play

Operational Overview

1:42 min overview

(spx® — solution)

Designing systems that replace coordination with execution

Reimbursement is where PGx programs win or bleed. Payers deny claims when coding, medical necessity, and clinical rationale do not line up — and labs absorb the loss or burn staff hours chasing appeals. The Revenue Defense Engine treats every report as a defensible claim from the moment it is generated.

It builds the reimbursement case at the point of interpretation — not after the denial arrives.

As each report is finalized, SignalAI assembles the coding, medical-necessity language, and citation trail that a payer expects to see — mapped to the ordered genes, the patient's medications, and the guideline basis for each recommendation. Nothing is auto-submitted: your medical director and billing team review the assembled evidence package and retain full control before it moves to the claim.

The module structures every element a payer scrutinizes:

Gene-to-code and medical-necessity mapping
Guideline-cited rationale per recommendation
Audit-ready evidence packages
Denial pattern tracking and flags

Consistency is what keeps a payer from finding an easy reason to deny. Every claim draws on the same structured logic and the same evidence sources — CPIC, FDA labeling, and DailyMed — so documentation reads the same across analysts, shifts, and volume. When guidance shifts, the underlying rationale updates, keeping the reimbursement case current rather than stale.

The engine fits the billing workflow you already run. Evidence packages export in the formats your revenue-cycle team and clearinghouse expect, coding aligns to your existing panels and order codes, and the module operates within the same HIPAA business-associate boundary as the rest of the platform — no separate data path, no new system for staff to learn.

At volume, the payoff compounds. Cleaner first-pass claims mean fewer denials to work, shorter appeals cycles, and billing staff spent on exceptions rather than reconstructing rationale one claim at a time. Denial-pattern signals surface where a specific payer or code is costing you, so you can fix the root cause instead of re-appealing the same rejection.

Labs protect more of the revenue their PGx testing earns, and clinicians see recommendations backed by documentation that holds up under review — without adding to the medical director's manual burden.

(spx® — Technology Stacks)

CPT

ICD-10

Z-Codes

MolDX

LOINC

(spx® — from the team)

Every report leaves the lab already coded, documented, and ready to defend.

Tarek Younis

Founder & CEO, SignalPGx

Previous case

Living Reanalysis & Alerts

Next case

EHR + CDS Integrations

0 +

PGx CPT Codes

0 %

Payer Policies Tracked

0 x

Audit-Ready Reports

Synapse

PGx Revenue Defense Engine

SignalPGx attaches payer-ready CPT and ICD-10 coding, MolDX Z-code context, and medical-necessity documentation to every pharmacogenomic report before it is released, so the lab's billing team reviews and signs off on a defensible, audit-ready claim instead of reconstructing the coding and rationale after a denial.

Year

2026

Industry

PGx Reimbursement & Revenue Integrity

SERVICE USED

Evidence Interpretation, Report Automation

Challenge

PGx claims are routinely denied because CPT coding, ICD-10 medical necessity, and MolDX Z-code documentation are assembled by hand after the report already shipped.

(spx® — the problem)

Pharmacogenomic claims are routinely denied when CPT coding, ICD-10 medical-necessity, and MolDX Z-code documentation are assembled by hand after a report ships, leaving billing teams to reconstruct the justification for every appeal.

Play

Operational Overview

1:42 min overview

(spx® — solution)

Designing systems that replace coordination with execution

Reimbursement is where PGx programs win or bleed. Payers deny claims when coding, medical necessity, and clinical rationale do not line up — and labs absorb the loss or burn staff hours chasing appeals. The Revenue Defense Engine treats every report as a defensible claim from the moment it is generated.

It builds the reimbursement case at the point of interpretation — not after the denial arrives.

As each report is finalized, SignalAI assembles the coding, medical-necessity language, and citation trail that a payer expects to see — mapped to the ordered genes, the patient's medications, and the guideline basis for each recommendation. Nothing is auto-submitted: your medical director and billing team review the assembled evidence package and retain full control before it moves to the claim.

The module structures every element a payer scrutinizes:

Gene-to-code and medical-necessity mapping
Guideline-cited rationale per recommendation
Audit-ready evidence packages
Denial pattern tracking and flags

Consistency is what keeps a payer from finding an easy reason to deny. Every claim draws on the same structured logic and the same evidence sources — CPIC, FDA labeling, and DailyMed — so documentation reads the same across analysts, shifts, and volume. When guidance shifts, the underlying rationale updates, keeping the reimbursement case current rather than stale.

The engine fits the billing workflow you already run. Evidence packages export in the formats your revenue-cycle team and clearinghouse expect, coding aligns to your existing panels and order codes, and the module operates within the same HIPAA business-associate boundary as the rest of the platform — no separate data path, no new system for staff to learn.

At volume, the payoff compounds. Cleaner first-pass claims mean fewer denials to work, shorter appeals cycles, and billing staff spent on exceptions rather than reconstructing rationale one claim at a time. Denial-pattern signals surface where a specific payer or code is costing you, so you can fix the root cause instead of re-appealing the same rejection.

Labs protect more of the revenue their PGx testing earns, and clinicians see recommendations backed by documentation that holds up under review — without adding to the medical director's manual burden.

(spx® — Technology Stacks)

CPT

ICD-10

Z-Codes

MolDX

LOINC

(spx® — from the team)

Every report leaves the lab already coded, documented, and ready to defend.

Tarek Younis

Founder & CEO, SignalPGx

Previous case

Living Reanalysis & Alerts

Next case

EHR + CDS Integrations

0 +

PGx CPT Codes

0 %

Payer Policies Tracked

Synapse

PGx Revenue Defense Engine

SignalPGx attaches payer-ready CPT and ICD-10 coding, MolDX Z-code context, and medical-necessity documentation to every pharmacogenomic report before it is released, so the lab's billing team reviews and signs off on a defensible, audit-ready claim instead of reconstructing the coding and rationale after a denial.

Year

2026

Industry

PGx Reimbursement & Revenue Integrity

SERVICE USED

Evidence Interpretation, Report Automation

Challenge

PGx claims are routinely denied because CPT coding, ICD-10 medical necessity, and MolDX Z-code documentation are assembled by hand after the report already shipped.

(spx® — the problem)

Pharmacogenomic claims are routinely denied when CPT coding, ICD-10 medical-necessity, and MolDX Z-code documentation are assembled by hand after a report ships, leaving billing teams to reconstruct the justification for every appeal.

Play

Operational Overview

1:42 min overview

(spx® — solution)

Designing systems that replace coordination with execution

Reimbursement is where PGx programs win or bleed. Payers deny claims when coding, medical necessity, and clinical rationale do not line up — and labs absorb the loss or burn staff hours chasing appeals. The Revenue Defense Engine treats every report as a defensible claim from the moment it is generated.

It builds the reimbursement case at the point of interpretation — not after the denial arrives.

As each report is finalized, SignalAI assembles the coding, medical-necessity language, and citation trail that a payer expects to see — mapped to the ordered genes, the patient's medications, and the guideline basis for each recommendation. Nothing is auto-submitted: your medical director and billing team review the assembled evidence package and retain full control before it moves to the claim.

The module structures every element a payer scrutinizes:

Gene-to-code and medical-necessity mapping
Guideline-cited rationale per recommendation
Audit-ready evidence packages
Denial pattern tracking and flags

Consistency is what keeps a payer from finding an easy reason to deny. Every claim draws on the same structured logic and the same evidence sources — CPIC, FDA labeling, and DailyMed — so documentation reads the same across analysts, shifts, and volume. When guidance shifts, the underlying rationale updates, keeping the reimbursement case current rather than stale.

The engine fits the billing workflow you already run. Evidence packages export in the formats your revenue-cycle team and clearinghouse expect, coding aligns to your existing panels and order codes, and the module operates within the same HIPAA business-associate boundary as the rest of the platform — no separate data path, no new system for staff to learn.

At volume, the payoff compounds. Cleaner first-pass claims mean fewer denials to work, shorter appeals cycles, and billing staff spent on exceptions rather than reconstructing rationale one claim at a time. Denial-pattern signals surface where a specific payer or code is costing you, so you can fix the root cause instead of re-appealing the same rejection.

Labs protect more of the revenue their PGx testing earns, and clinicians see recommendations backed by documentation that holds up under review — without adding to the medical director's manual burden.

(spx® — Technology Stacks)

CPT

ICD-10

Z-Codes

MolDX

LOINC

(spx® — from the team)

Every report leaves the lab already coded, documented, and ready to defend.

Tarek Younis

Founder & CEO, SignalPGx

Previous case

Living Reanalysis & Alerts

Next case

EHR + CDS Integrations

0 +

PGx CPT Codes

0 %

Payer Policies Tracked

0 x

Audit-Ready Reports

Synapse

PGx Revenue Defense Engine

SignalPGx attaches payer-ready CPT and ICD-10 coding, MolDX Z-code context, and medical-necessity documentation to every pharmacogenomic report before it is released, so the lab's billing team reviews and signs off on a defensible, audit-ready claim instead of reconstructing the coding and rationale after a denial.

Year

2026

Industry

PGx Reimbursement & Revenue Integrity

SERVICE USED

Evidence Interpretation, Report Automation

Challenge

PGx claims are routinely denied because CPT coding, ICD-10 medical necessity, and MolDX Z-code documentation are assembled by hand after the report already shipped.

(spx® — the problem)

Pharmacogenomic claims are routinely denied when CPT coding, ICD-10 medical-necessity, and MolDX Z-code documentation are assembled by hand after a report ships, leaving billing teams to reconstruct the justification for every appeal.

Play

Operational Overview

1:42 min overview

(spx® — solution)

Designing systems that replace coordination with execution

Reimbursement is where PGx programs win or bleed. Payers deny claims when coding, medical necessity, and clinical rationale do not line up — and labs absorb the loss or burn staff hours chasing appeals. The Revenue Defense Engine treats every report as a defensible claim from the moment it is generated.

It builds the reimbursement case at the point of interpretation — not after the denial arrives.

As each report is finalized, SignalAI assembles the coding, medical-necessity language, and citation trail that a payer expects to see — mapped to the ordered genes, the patient's medications, and the guideline basis for each recommendation. Nothing is auto-submitted: your medical director and billing team review the assembled evidence package and retain full control before it moves to the claim.

The module structures every element a payer scrutinizes:

Gene-to-code and medical-necessity mapping
Guideline-cited rationale per recommendation
Audit-ready evidence packages
Denial pattern tracking and flags

Consistency is what keeps a payer from finding an easy reason to deny. Every claim draws on the same structured logic and the same evidence sources — CPIC, FDA labeling, and DailyMed — so documentation reads the same across analysts, shifts, and volume. When guidance shifts, the underlying rationale updates, keeping the reimbursement case current rather than stale.

The engine fits the billing workflow you already run. Evidence packages export in the formats your revenue-cycle team and clearinghouse expect, coding aligns to your existing panels and order codes, and the module operates within the same HIPAA business-associate boundary as the rest of the platform — no separate data path, no new system for staff to learn.

At volume, the payoff compounds. Cleaner first-pass claims mean fewer denials to work, shorter appeals cycles, and billing staff spent on exceptions rather than reconstructing rationale one claim at a time. Denial-pattern signals surface where a specific payer or code is costing you, so you can fix the root cause instead of re-appealing the same rejection.

Labs protect more of the revenue their PGx testing earns, and clinicians see recommendations backed by documentation that holds up under review — without adding to the medical director's manual burden.